A meta-analysis in eClinicalMedicine finds vaccines are safe for pregnant women living with HIV, showing reduced immunogenicity compared to those without HIV but no increase in adverse events, highlighting the need for their inclusion in vaccine trials.
By Dr. Chinta SidharthanFeb 9 2024Reviewed by Susha Cheriyedath, M.Sc. In a recent study published in the journal eClinicalMedicine, researchers performed a meta-analysis on the immunogenicity and safety of vaccines for pregnant women living with human immunodeficiency virus infections , comparing their immunogenicity effect to those without HIV infections .
About the study In the present meta-analysis, researchers examined the immunogenicity and safety of vaccines for HIV-exposed pregnant women. The researchers followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for analysis. They used the Newcastle-Ottawa Scale to assess the methodological quality of non-randomized controlled trials. Three researchers evaluated bias risks related to generating random sequences, allocation concealing, personnel and participant blinding, outcome assessment blinding, selective reporting, and inadequate outcome data.
Related StoriesFive studies, including 3,456 PWLWH women, reported safety outcomes, with no increase in adverse events reported in PWLWH compared to PWWH. The GMT increase from baseline to weeks 28-35 post-vaccination in HA units ranged between 12 and 239. The pooled geometric mean difference in hemagglutination inhibition titers following influenza vaccination was 56. The increase was less in PWLWH compared to PWWH: −142.